Log In
Print
BCIQ
Print
Print this Print this
 

Vesomni, solifenacin/tamsulosin (EC905)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionFixed-dose combination of solifenacin and tamsulosin
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentApproved
Standard Indication Genitourinary (unspecified)
Indication DetailsTreat lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH); Treat moderate to severe storage symptoms and voiding symptoms associated with benign prostatic hyperplasia (BPH)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today